After adjusting for age, disease stage, tumor grade, ER status, PR status, HER2 status, surgery status, and radiation treatment, survival for GRCC remained significantly poorer compared to non-GRCC carcinomas (HR: 1.33; 95% CI: 1.04–1.67; p = 0.025). The gene discussed is ERBB2; the disease is neoplasm.